These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 18272909)
41. Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma. Zeis M; Zunkel T; Steinmann J; Schmitz N; Uharek L Br J Haematol; 2002 Apr; 117(1):93-102. PubMed ID: 11918538 [TBL] [Abstract][Full Text] [Related]
42. Translational development of active immunotherapy for hematologic malignancies. Kwak LW Semin Oncol; 2003 Jun; 30(3 Suppl 8):17-22. PubMed ID: 12881808 [TBL] [Abstract][Full Text] [Related]
43. Prolonged idiotypic vaccination against follicular lymphoma. Inoges S; Lopez-Diaz de Cerio A; Zabalegui N; Soria E; Villanueva H; Panizo C; Rodriguez-Caballero A; Suarez L; Pastor F; Rodriguez-Calvillo M; Orfao A; Bendandi M Leuk Lymphoma; 2009 Jan; 50(1):47-53. PubMed ID: 19152172 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results. Zahradova L; Mollova K; Ocadlikova D; Kovarova L; Adam Z; Krejci M; Pour L; Krivanova A; Sandecka V; Hajek R Neoplasma; 2012; 59(4):440-9. PubMed ID: 22489700 [TBL] [Abstract][Full Text] [Related]
45. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Li Y; Bendandi M; Deng Y; Dunbar C; Munshi N; Jagannath S; Kwak LW; Lyerly HK Blood; 2000 Oct; 96(8):2828-33. PubMed ID: 11023518 [TBL] [Abstract][Full Text] [Related]
46. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. Cohen S; Haimovich J; Hollander N J Immunother; 2005; 28(5):461-6. PubMed ID: 16113602 [TBL] [Abstract][Full Text] [Related]
47. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Qazilbash MH; Saini NY; Cha SC; Wang Z; Stadtmauer EA; Baladandayuthapani V; Lin H; Tross B; Honhar M; Rao SS; Kim K; Popescu M; Szymura S; Zhang T; Anderson A; Bashir Q; Shpall EJ; Orlowski RZ; Levine BL; Kerr N; Garfall A; Cohen A; Vogl DT; Dengel K; June CH; Champlin R; Kwak LW Blood; 2022 Mar; 139(9):1289-1301. PubMed ID: 34521108 [TBL] [Abstract][Full Text] [Related]
48. Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. McCann KJ; Godeseth R; Chudley L; Mander A; Di Genova G; Lloyd-Evans P; Kerr JP; Malykh VB; Jenner MW; Orchard KH; Stevenson FK; Ottensmeier CH Cancer Immunol Immunother; 2015 Aug; 64(8):1021-32. PubMed ID: 25982371 [TBL] [Abstract][Full Text] [Related]
50. Idiotypic vaccination as therapy for multiple myeloma. Kwak LW; Thielemans K; Massaia M Semin Hematol; 1999 Jan; 36(1 Suppl 3):34-7. PubMed ID: 9989488 [TBL] [Abstract][Full Text] [Related]
51. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Cull G; Durrant L; Stainer C; Haynes A; Russell N Br J Haematol; 1999 Dec; 107(3):648-55. PubMed ID: 10583271 [TBL] [Abstract][Full Text] [Related]
52. Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma. Kunkel LA Cancer Invest; 2004; 22(1):97-105. PubMed ID: 15069767 [No Abstract] [Full Text] [Related]
53. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission. Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966 [No Abstract] [Full Text] [Related]